由于安全问题, Eisai 要求 TGA 重新考虑 lecanemab 作为阿尔茨海默氏症药物. Eisai seeks TGA reconsideration of lecanemab Alzheimer's drug rejection due to safety concerns.

日本一家制药公司Eisai计划请澳大利亚治疗物品管理局(TGA)重新考虑其拒绝Lecanemab的说法, Eisai, a Japanese pharmaceutical firm, plans to ask Australia's Therapeutic Goods Administration (TGA) to reconsider its rejection of lecanemab, an Alzheimer's treatment already approved in several countries, including the U.S. TGA提到对大脑可能膨胀和出血的安全关切。 The TGA cited safety concerns over potential brain swelling and bleeding. 虽然该药物在减缓认知下降方面有希望,但其高昂的成本和风险引发了对其有效性和安全性的重大辩论。 While the drug has shown promise in slowing cognitive decline, its high cost and risks have sparked significant debate on its effectiveness and safety.